Mark J. Gergen Sells 30,000 Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) Stock

Poseida Therapeutics, Inc. (NASDAQ:PSTX) Chairman Mark J. Gergen sold 30,000 shares of the company’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total transaction of $278,100.00. Following the completion of the transaction, the chairman now owns 651,291 shares in the company, valued at $6,037,467.57. This represents a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Poseida Therapeutics Price Performance

Shares of PSTX opened at $9.33 on Friday. Poseida Therapeutics, Inc. has a twelve month low of $1.87 and a twelve month high of $9.42. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20. The company has a 50 day moving average of $3.14 and a two-hundred day moving average of $3.05.

Analyst Upgrades and Downgrades

PSTX has been the topic of a number of recent research reports. William Blair reiterated a “market perform” rating on shares of Poseida Therapeutics in a research note on Tuesday. Cantor Fitzgerald downgraded shares of Poseida Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. HC Wainwright reiterated a “neutral” rating and set a $9.00 price objective (down from $20.00) on shares of Poseida Therapeutics in a research note on Tuesday. Finally, BTIG Research reiterated a “neutral” rating on shares of Poseida Therapeutics in a research note on Tuesday. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, Poseida Therapeutics presently has an average rating of “Hold” and an average target price of $9.50.

Institutional Investors Weigh In On Poseida Therapeutics

Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its stake in Poseida Therapeutics by 53.4% in the second quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock valued at $2,496,000 after acquiring an additional 297,500 shares in the last quarter. Advantage Alpha Capital Partners LP purchased a new position in shares of Poseida Therapeutics in the third quarter worth $285,000. Vanguard Group Inc. raised its holdings in shares of Poseida Therapeutics by 16.3% in the first quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock worth $10,760,000 after buying an additional 473,746 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Poseida Therapeutics by 62.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 359,197 shares of the company’s stock worth $1,027,000 after buying an additional 138,510 shares during the last quarter. Finally, Public Employees Retirement System of Ohio raised its holdings in shares of Poseida Therapeutics by 177.3% in the first quarter. Public Employees Retirement System of Ohio now owns 62,945 shares of the company’s stock worth $201,000 after buying an additional 40,245 shares during the last quarter. 46.87% of the stock is currently owned by institutional investors and hedge funds.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.